Mushrooms & Diabetes / Blood Sugar
2023 systematic review
Kenyon et al.'s 2023 systematic review of mushroom consumption and cardiometabolic risk found suggestive evidence for triglyceride reduction and hs-CRP improvement, limited evidence for HbA1c improvement, and no clear benefit for LDL or blood pressure. This is the most current honest summary of where the evidence actually stands.
Kenyon et al., Nutrients, 2023
n=84
participants in Feeney 2016's double-blind Reishi RCT that found no metabolic improvement on any primary outcome
Triglycerides
the metabolic syndrome marker with the clearest evidence of improvement from mushroom consumption
2024
year of the first prospective cohort study directly linking dietary mushroom intake to type 2 diabetes risk
Kenyon et al., Nutrients, 2023
View as image ↗Here is a finding that most mushroom supplement brands will not tell you: the most rigorous human trial of mushroom supplementation for metabolic syndrome published to date found no benefit. Feeney and colleagues ran a double-blind, placebo-controlled RCT with 84 participants and 16 weeks of reishi supplementation, measuring HbA1c (average blood sugar), fasting glucose, lipids, and blood pressure. The result across all primary and secondary outcomes was null.[5]
That finding is where an honest article on mushroom consumption metabolic syndrome evidence has to start. Not because mushrooms are useless for metabolic health, but because this null result shapes how to read every other study in this area. It also makes the evidence that does hold up more credible, not less.
Kenyon and colleagues' 2023 systematic review in Nutrients synthesized the current state of the evidence honestly: mushroom consumption shows suggestive associations with improved triglycerides and reduced inflammation markers; the evidence for HbA1c improvement is limited and mixed; the evidence for LDL and blood pressure is weak.[1]
This article maps the full picture. For species-specific deep dives, see reishi for metabolic syndrome, mushrooms targeting the five metabolic syndrome criteria, and the diabetes pillar.
Key Takeaways
- Kenyon et al.'s 2023 systematic review found suggestive evidence for triglyceride reduction and inflammation (hs-CRP) improvement from mushroom consumption, but limited evidence for HbA1c and no clear evidence for LDL or blood pressure
- Feeney et al.'s 2016 double-blind RCT (n=84, 16 weeks, reishi with or without Cordyceps) found null results across all four metabolic syndrome outcome measures: HbA1c, fasting glucose, lipids, and blood pressure
- A 2024 prospective cohort study found that higher dietary mushroom intake was associated with lower risk of developing type 2 diabetes, providing population-level evidence beyond supplement studies
- Feeney et al.'s 2016 retrospective study found daily white button mushroom consumption (100g/day for 16 weeks) significantly increased antioxidant capacity and adiponectin while reducing oxidative stress markers, suggesting dietary mushrooms may reduce metabolic risk through anti-inflammatory pathways even without directly improving glucose markers
- Musso et al. (2020) and Guillamón et al. (2013) mapped the mechanistic rationale: mushroom polysaccharides, beta-glucans, phenolics, and terpenoids each address different metabolic syndrome criteria through different pathways, but preclinical evidence does not consistently translate to human clinical benefit
- The clearest practical conclusion: dietary mushroom consumption likely supports cardiometabolic health through inflammation and triglyceride pathways; targeted mushroom supplementation for glucose control has not been convincingly demonstrated in rigorous trials
What Metabolic Syndrome Is (And Why Mushroom Research Targets It)
Metabolic syndrome is not a single disease. It is a cluster of conditions that together substantially raise the risk of heart disease, stroke, and type 2 diabetes when they occur simultaneously. The formal definition requires three or more of five criteria: elevated waist circumference (central obesity), elevated fasting blood glucose, elevated triglycerides (fats in the blood), low HDL cholesterol (the "good" cholesterol), and elevated blood pressure.
Roughly one-third of adults in the United States meet the criteria for metabolic syndrome. It is driven by insulin resistance, chronic low-grade inflammation, and metabolic dysregulation, and it precedes type 2 diabetes by years in many cases.
Mushrooms have attracted research attention for metabolic syndrome because their bioactive compounds target multiple pathways simultaneously. Musso and colleagues' 2020 review in International Journal of Molecular Sciences catalogued the mechanisms: polysaccharides and beta-glucans address glucose control and cholesterol; triterpenoids address inflammation and lipid metabolism; phenolics inhibit enzymes involved in carbohydrate digestion; sterols affect cholesterol synthesis.[2] Each compound class targets a different pathway, and most edible mushrooms contain several.
The question is whether these mechanistic pathways produce detectable clinical benefits in humans. The evidence is more nuanced than either "yes, mushrooms treat metabolic syndrome" or "no, it's all hype."
What the Research Shows: A Metabolic Marker by Marker Breakdown
| Metabolic marker | Evidence from mushroom consumption | Strength |
|---|---|---|
| Triglycerides | Some reduction in observational and supplementation studies | Moderate |
| hs-CRP (inflammation) | Some reduction in human studies | Moderate |
| Fasting blood glucose | Inconsistent; some positive trials, major RCT found null | Weak-Moderate |
| HbA1c (3-month blood sugar) | Limited; one positive prediabetes RCT, one major null RCT | Limited |
| LDL cholesterol | No clear benefit in human studies | Weak |
| Blood pressure | No clear benefit in human studies | Weak |
| Waist circumference | Some evidence from recent prediabetes trial | Emerging |
Kenyon's 2023 systematic review reached essentially these conclusions: mushroom consumption is most consistently associated with triglyceride improvement and reduced inflammation; the evidence for direct blood sugar and lipid benefits is less robust.[1] The reviewers noted that most positive human trials were small, short, and conducted with specific mushroom preparations that may not generalize to dietary consumption patterns.
Where the Evidence Is Strongest: Triglycerides and Inflammation
Mushroom polysaccharides, particularly beta-glucans, affect lipid metabolism through several mechanisms. Beta-glucans are viscous dietary fibers that bind bile acids in the intestine. Bile acids are made from cholesterol; when they are trapped by beta-glucan and excreted rather than reabsorbed, the liver must use circulating cholesterol to make new bile acids, reducing blood cholesterol levels. This mechanism is well-documented for oat beta-glucans and less studied but plausible for mushroom beta-glucans.
Guillamón and colleagues' 2013 review specifically noted that beta-glucans from mushrooms may lower cholesterol through this bile acid sequestration pathway, and that mushroom polyphenols inhibit alpha-glucosidase, an enzyme that breaks down carbohydrates in the gut.[3] Blocking this enzyme slows the conversion of starch and sugars into glucose, reducing postprandial blood sugar spikes.
The anti-inflammatory evidence comes partly from the dietary mushroom data. Feeney and colleagues' 2016 retrospective study of metabolic syndrome adults consuming 100g of white button mushrooms daily for 16 weeks found significantly increased adiponectin levels and reduced oxidative stress markers compared to baseline.[4] Adiponectin is an anti-inflammatory hormone secreted by fat tissue; low adiponectin is associated with insulin resistance and metabolic syndrome. The white button mushroom consumption did not significantly improve fasting glucose or HbA1c in this study, but the anti-inflammatory effects were clear.
This distinction matters: mushroom consumption may reduce metabolic syndrome risk through anti-inflammatory and lipid pathways even without directly lowering blood glucose. Since chronic inflammation is both a driver and a consequence of metabolic syndrome, reducing it may be part of how dietary mushrooms provide cardiometabolic benefit even when glucose markers don't respond.
The Null Result That Changes the Picture
In 2016, Feeney and colleagues published what remains the most rigorous human trial of mushroom supplementation for metabolic syndrome in Scientific Reports.[5]
The design was strong: 84 participants with metabolic syndrome, 16 weeks, double-blind, placebo-controlled. Participants received reishi mushroom extract alone, reishi combined with Cordyceps, or placebo. The outcomes measured were the four most relevant metabolic markers: HbA1c (average blood sugar), fasting glucose, blood lipids (triglycerides, LDL, HDL), and blood pressure.
None of the primary or secondary outcomes showed significant improvement in either mushroom group compared to placebo.
No HbA1c benefit. No fasting glucose benefit. No lipid benefit. No blood pressure benefit.
This is a null result from a well-designed trial, and it matters. Earlier, smaller trials of reishi for metabolic markers had shown positive trends, and a 2015 systematic review by Klupp and colleagues found modest short-term reductions in blood glucose and blood pressure from reishi in earlier studies, but noted that reporting quality was poor with high risk of bias.[6] The Feeney 2016 RCT tested the hypothesis under adequately controlled conditions and found it did not hold.
What might explain the null result? Several possibilities: the specific reishi extract used may not have contained the bioactive concentrations studied in preclinical models; the dose may have been insufficient; metabolic syndrome patients on standard-of-care interventions may have limited room for additional supplemental benefit; or the preclinical animal models simply don't translate to humans in this context.
All of these are honest explanations for a common phenomenon in nutritional science: compelling preclinical evidence and plausible mechanisms that fail to produce clinical effects when tested rigorously. The honest position is that reishi supplementation for metabolic syndrome has not been demonstrated to work in the most rigorous human trial conducted.
This does NOT mean dietary mushroom consumption has no metabolic benefit. The Feeney null result is specifically about reishi extract supplementation in metabolic syndrome patients. It says less about the effects of regular dietary mushroom consumption over years, or the effects of oyster mushrooms, Tremella, or maitake with different bioactive profiles and mechanisms. But it should anchor any discussion of targeted mushroom supplementation for metabolic syndrome.
The Population Evidence: Dietary Mushrooms and T2D Risk
Supplementation trials answer a specific question: does adding mushroom extract change metabolic outcomes over weeks? Epidemiological studies answer a different question: do people who habitually eat more mushrooms have better metabolic outcomes over years?
A 2024 prospective cohort study examined the association between dietary mushroom intake and the risk of developing type 2 diabetes in a population followed over time.[7] Prospective cohort studies (where participants are followed forward from a baseline, rather than looking back at history) are stronger epidemiological designs than cross-sectional or retrospective approaches. This study provides population-level evidence that habitual mushroom eating is associated with lower T2D incidence.
The limitation of prospective cohort data: people who eat more mushrooms may also have healthier diets overall, be more physically active, and have other lifestyle factors that account for the T2D risk reduction. Observational studies cannot rule out confounding. But when multiple cohort studies across different populations (Singapore, US, China, Japan for cognitive outcomes; comparable studies for metabolic outcomes) consistently show the same direction of association, the consistency itself is informative.
The combination of the prospective population data (mushroom eating predicts lower T2D risk), the mechanistic evidence (multiple pathways through which mushroom bioactives affect metabolism), and the specific positive clinical data on inflammation and triglycerides suggests that dietary mushroom consumption likely does support cardiometabolic health over time, even if targeted high-dose supplementation studies have been disappointing.
What the Evidence Means for Dietary Mushrooms vs. Supplements
The picture assembled from this research points to an important distinction.
Dietary mushroom consumption has suggestive population-level evidence (prospective T2D risk reduction), meaningful anti-inflammatory effects in dietary intervention studies (Feeney retrospective: adiponectin, oxidative stress markers), and plausible mechanistic rationale for multiple metabolic pathways. The evidence supports regular dietary consumption as part of a cardiometabolic health strategy.
Targeted mushroom supplementation for metabolic syndrome has been tested most rigorously in reishi, and the most rigorous trial found null results. The positive supplement trial data that exists comes from specific populations (prediabetes patients with Tremella, impaired glucose tolerance patients with oyster mushroom) using specific species, formulations, and doses. These warrant attention but do not generalize to broad "mushroom supplements for metabolic syndrome" claims.
For readers with metabolic syndrome looking at dietary approaches: the evidence most clearly supports mushrooms as a regular dietary food contributing to triglyceride reduction, inflammation control, and long-term T2D risk reduction through regular consumption. For the prediabetes and HbA1c angle, see mushrooms for prediabetes and the mushroom diet and HbA1c.
For the maitake-specific metabolic evidence (including the SX-fraction research on insulin sensitivity), see maitake and metabolic regulation.
The Bottom Line
The most rigorous human trial of mushroom supplementation for metabolic syndrome, Feeney et al.'s 2016 double-blind RCT of 84 participants, found no improvement in HbA1c, fasting glucose, lipids, or blood pressure from reishi supplementation. Kenyon et al.'s 2023 systematic review confirmed this honest picture: mushroom consumption shows suggestive evidence for triglyceride reduction and inflammation improvement, limited evidence for HbA1c improvement, and no clear benefit for LDL or blood pressure. A 2024 prospective cohort study found higher dietary mushroom intake associated with lower T2D risk, and Feeney et al.'s retrospective dietary study found 100g/day of white button mushrooms improved anti-inflammatory and antioxidant markers. The evidence supports dietary mushroom consumption as part of cardiometabolic health management through anti-inflammatory and lipid pathways, while targeted supplementation for glucose control remains unproven in the most rigorous trials.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.